Back to articles

Imatinib: Patients with Chronic Myeloid Leukemia Have New Alternative when Transplantation Is Not Feasible


In patients with newly diagnosed chronic myeloid leukemia (CML) who are not suitable candidates for hematopoietic stem-cell transplantation, imatinib mesylate (Gleevec—Novartis) is emerging as the best alternative treatment. Results with the tyrosine kinase inhibitor have been so positive that clinicians are considering ways to incorporate imatinib into treatment regimens even while transplantation possibilities are being evaluated.


O’Brien SG et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004.

Peggs K, Mackinnon S. Imatinib mesylate—the new gold standard for treatment of chronic myeloid leukemia [editorial]. N Engl J Med. 2003;348:1048–50.